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ABSTRACT 
It has recently been proposed that the development of behavioral sensitization to 
psychostimulant drugs is mediated by a repeated drug-induced alteration in dopamine D3 
receptors. Consistent with this hypothesis, concurrent treatments with the preferential 
dopamine D3 receptors antagonist, nafadotride, has been reported to prevent the development 
of behavioral sensitization to amphetamine. This dopamine D3 hypothesis was further tested 
in the present study by determining whether nafadotride would also prevent the development 
of behavioral sensitization to cocaine. 
At the beginning of this experiment, male Wistar rats (250-300g) were tested for 
activity after a saline injection on two days. Based on the distance traveled on the second day, 
the subjects were divided into four drug treatment groups: vehicle-vehicle, vehicle-cocaine, 
nafadotride-vehicle, and nafadotride-cocaine. From Day 3 to Day 6 (drug treatment phase), 
the subjects received daily I. P. injection with vehicle, cocaine, nafadotride, or cocaine+ 
nafadotride, respectively. Five minutes after each daily injection, the rats were placed into the 
activity boxes (Med-Associates model OFA-163) for 40 minutes. On the 7th and 8th days 
(conditioning test phase), all rats received saline ittjections prior to activity testing. On the 
last day (Day 9), each subject was given a challenge injection of cocaine followed by activity 
testing. 
The results indicated that repeated cocaine treatments produced a progressively 
greater increase in activity (i.e. behavioral sensitization). In contrast, repeated nafadotride 
treatments did not significantly affect locomotor activity. More important, concurrent 
treatment ofnafadotride with cocaine did not affect either the cocaine-induced acute or 
chronic locomotor effect. On the drug-withdrawal days, rats previously treated with cocaine 
displayed a conditioned hyperactivity response, which was not prevented by concurrent 
nafadotride treatment. Further, the cocaine challenge injection produced a significantly 
greater increase in activity in rats previously treated cocaine, compared to rats injected with 
cocaine for the first time. Finally, pretreatment with nafadotride and cocaine did not block the 
development of sensitization to cocaine. In fact, concurrent nafadotride-cocaine 
pretreatments tended to produce an even greater increase in cocaine-induced activity than the 
cocaine pretreatments alone. Thus, if anything, nafadotride treatments tended to enhance the 
development of the behavioral sensitization to cocaine. 
These findings clearly do not support the hypothesis that the development of 
behavioral sensitization to cocaine is mediated through changes in dopamine D3 receptors. 
Furthermore, these findings suggest that the development of behavioral sensitization to 
different psychostimulant"drugs may be mediated by different neurochemical mechanisms. 
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Drug abuse is a global phenomenon. It affects almost every country. Drug 
abuse trends around the world, especially among youth, have become a very serious 
issue in the last a few decades. For example, heroin abuse is reported in three-quarters 
of all countries and abuse of cocaine is reported in two-thirds. Drug-related problems 
include increased rates of crime and violence, susceptibility to HIV/ AIDS and 
hepatitis, demand for treatment and emergency-room visits and a breakdown in social 
behavior (UNODCCP report, 2001 ). 
Curativeness, religion, and recreation have been the main reasons for people 
to use psychoactive drugs for many years. However, at the end of the last century, due 
to the development of science, especially in the field of chemistry and pharmacology, 
stronger, more pure and highly addictive substances such as cocaine and heroin were 
synthesized. In addition, the invention of hypodermic syringes enabled people to 
inject these drugs, making their effects more powerful and the risk of addiction more 
serious (UNOCCP report, 2001). 
Currently, the mechanism mediating drug addiction has become a major focus 
in the area of psychology and neuroscience. "The central feature of drug addiction is 
compulsive drug use-loss of control over apparently voluntary acts of drug seeking 
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and drug taking" (Goldstein, 1994). Drugs have both acute and chronic effects on 
behavior. If they are used repeatedly, some acute drug effects may become less, 
which is called tolerance; while others become higher which is considered 
sensitization. Generally, drug addiction studies include drug-conditioning effect and 
drug-brain adaptation. The former focuses on the role of classical and operant 
conditioning mechanism in mediating drug addiction. The latter stresses on the role of 
specific brain mechanisms to drug addiction. Two different types of brain responses 
to drug addiction have been proposed for: 1) neural adaptations, which includes 
homeostatic response to excessive stimulation; and 2) synaptic plasticity, which 
associates drug related stimuli with specific learned behavior (Berke' & Hyman, 
2000). 
Behavioral Sensitization 
Initially, repeated drug use produces withdrawal effects, such as craving in 
humans. In turn, addiction is observed, which is represented by the. compulsive drug 
seeking behaviors (Robinson & Berridge, 1993; Robinson & Becker, 1986). 
However, it is difficult to experimentally study the neural and behavioral mechanism 
of drug addiction in humans. Therefore, many researchers have developed animal 
models to study the different aspects of the drug addiction process. Behavioral 
sensitization is one of the most frequently observed behavioral effects with the 
repeated administration of psychostimulant drugs in animals (Kalivas & Stewart, 
1991 ). Behavioral sensitization refers to "the finding that animals given several drug 
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injections spaced out at intervals of a day or more tend to show sensitized locomotor 
activity and stereotypy, progressively increasing with each injection" (Goldstein, 
1994). Due to the similarities between the drug addiction in humans and the 
behavioral sensitization in animals, behavioral sensitization has become a widely 
used model to study the mechanisms of drug addiction, particularly craving 
(Robinson & Berridge, 1993). 
Dopamine Receptor and Behavioral Sensitization 
Dopamine is crucial to a wide variety of behaviors and functions, which 
include the behavioral changes from sensitization to addiction, from movement to 
emotion, and development to plasticity (Joyce, 2001). "In part, this diversity reflects 
multiplicity of the organization and types of dopamine receptors, the neurons that 
express those receptors, and their source of dopamine innervations" (Joyce, 2001). 
Thus, dopamine receptors receive a lot of attention in drug abuse research. 
There are at least five types of dopamine receptors in the vertebrate CNS, and 
these fall into two classes: DI-type (DI and D5) and D2-type (D2, D3 and D4). 
Dopamine DI-type receptors are localized on the membrane of postsynaptic neurons, 
while the D2-type receptors are found on the membrane of both pre and post synaptic 
neurons. Early research suggested that stimulation of dopamine receptors was crucial 
to the development of behavioral sensitization, particularly the repeated stimulation 
of DI-type receptors (Henry & White, 1991). For example, concurrent treatment with 
selective DI-type (SCH 23390), but not D2-type (Sulpride), dopamine antagonists 
prevents the development of behavioral sensitization to the direct dopamine agonist, 
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apomorphine (Mattingly, Rowlett, Graff & Hatton, 1991) and the indirect agonist, 
amphetamine (Stewart & Vezina, 1989; Drew & Glick, 1990). In.addition, animals 
repeatedly treated with the selective DI-type dopamine agonist, SKF 38393, 
subsequently show a sensitized locomotor response to apomorphine (Mattingly, 
Rowlett & Lovell, 1993). These and other similar findings led to the view that the 
development of behavioral sensitization to different drugs was mediated by a 
commpn neurochemical mechanism, especially stimulation of dopamine DI receptors 
(White, Joshi, Koeltzow & Hu, 1998). However, recent studies with cocaine have 
questioned this assumption. For example, concurrent treatment with the DI receptor 
antagonist, SCH 23390, has consistently failed to prevent the development of the 
cocaine-induced behavioral sensitization (Mattingly, Hart, Lim & Perkins, 1994; 
Mattingly et al., 1996; White et al., 1998). Moreover, neither the D2 receptor 
antagonist ( eticlopride) nor concurrent treatment with both DI and D2 receptor 
antagonists (SCH 23390 + eticlopride) prevent the development of behavioral 
sensitization to cocaine (White et al., 1998). Thus, treatments with DI-type, D2-type 
or a combination ofDI- and D2-type dopamine receptor antagonists failed to prevent 
the development of behavioral sensitization to cocaine. These findings suggest that 
the development of behavioral sensitization to different drugs, such as cocaine, 
amphetamine, or apomorphine, may be mediated by different neurochemical 
mechanisms. 
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Dopamine D3 receptors and Behavioral Sensitization 
. As mentioned previously, three individual dopamine receptors (D2, D3 and 
D4) have been classified as D2-type receptors (Berke & Hyman, 2000). Recent 
research suggests that these subtypes are differentially expressed in the regions of 
human brain, providing a rationale for how they could mediate different actions of 
dopamine (see Berke & Hyman, 2000, for review). For example, D3 receptors, in 
contrast to D 1 and D2 dopamine receptors, have a restricted pattern of expression in 
the nucleus accumbens, which appears to be a critical structure in the control of 
motivation and the effects of drug-conditioned cues (Bouthenet, Souil, Martres, 
Sokoloff, Giros & Schwartz, 1991 ). Because of this unique distribution, dopamine D3 
receptors have been proposed to play a major role in various neuropsychiatric and 
neurological disorders (Joyce, 2001). 
Recently, it has been hypothesized that the development of behavioral 
sensitization to psychostimulant drugs may be related to the differential down-
regulation of dopamine D3 receptors compared to D 1/D2 receptors (Richtand, Logue, 
Welge, Perdiue, Tubbs, Spitzer, Sethuraman & Geracioti, 2000). This hypothesis is 
based upon several converging lines of evidence. First, considerable evidence exists 
which suggests that dopamine D 1/D2 and dopamine D3 receptors play opposing roles 
in the regulation oflocomotor behavior. Specifically, the selective stimulation of 
dopamine D 1/D2 receptors results in the stimulation oflocomotor activity in rodents, 
whereas the selective stimulation of dopamine D3 receptors inhibit locomotor activity 
(Ekman, Nissbrandt, Heilig, Dijkstra & Erikson, 1998; Sautel, Griffon, Sokoloff, 
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Schwartz, Launay, Simon, Costentin, Schoenfelder, Garrido & Mann, 1995). Thus, 
the level of locomotor activity is dependent upon the relative levels of stimulation of 
D l/D2 vs. D3 receptors. Second, a great deal of evidence suggests that repeated 
stimulation ofreceptors results in a homeos!atic down-regulation in proportion to the 
degree of overstimulation (Richtand, Woods, Berger & Strakowski, 200 I). Since 
dopamine has been reported to have a 70-fold g_reater affinity for D3 receptors 
compared to D 1/D2 receptors (Sololoff, Martres, Giros, Bouthenet & Schwartz, 
1992), it has been hypothesized that D3 receptors should undergo greater down-
regulation than D 1/D2 receptors with repeated psychostimulant treatments (Richtand 
et al., 2000). Thus, the progressive increase in locomotor activity (i.e., sensitization) 
observed with repeated psychostimulant administration might be due to a progressive 
decrease in DJ-mediated behavioral inhibition (i.e., disinhibition) resulting from D3 
receptor tolerance or down-regulation (Richtand et al., 2000). Consistent with this 
hypothesis, Richtand et al. (2000) reported that concurrent treatment with the 
selective dopamine D3 receptor antagonist, nafadotride, along with amphetamine 
blocked the development of behavioral sensitization to amphetamine. Presumably, 
nafadotride blocked the development of amphetamine-induced behavioral 
sensitization by preventing the down-regulation of D3 receptors. In addition, 
Mattingly, Fields, Langfels, Rowlett, Robinet and Bardo (1996) found that co-
administration of cocaine and the dopamine D3 receptor agonist, 7-OH-DP AT 
acutely attenuated cocaine-induced increases in motor behavior but enhanced the 
development of behavioral sensitization to cocaine. Based upon the above hypothesis, 
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this could be attributed to a 7-OH-DPAT-induced enhancement ofD3 receptor down-
regulation or tolerance. 
Although Richtand et al. (2000) present a persuasive argument for a role of 
dopamine D3 receptors in the development of behavioral sensitization, a number of 
findings.are inconsistent with their hypothesis. For example, the number of binding 
sites for D3 receptors has been reported to· be significantly elevated, rather than 
diminished, in cocaine-overdose victims (Staley & Mash, 1996). Furthermore, the 
locomotor inhibitory effect ofa low dose of the selective D3 agonist PD128, 927 was 
unaffected by prior sensitization to cocaine (Prinssen, Koek and Kleven 1998). In 
addition, concurrent treatment with the selective dopamine D3 receptor antagonist 
U99194A and cocaine does not affect the development of behavioral sensitization to 
cocaine (Mattingly, Caudill, Abel, Sutherland, & Dong, 2000). Finally, repeated 
treatment with the selective dopamine D3 receptor agonist 7-OH-DPAT does not 
produce sensitization or cross-sensitization to cocaine or apmorphine (Mattingly et 
al., 1996). Thus, the involvement of dopamine D3 receptors in the development of 
behavioral sensitization to psychostimulant drugs remains unclear. 
Purpose of Current Experiment 
As noted previously, it has been reported that concurrent treatment with the 
putatively selective dopamine D3 receptor antagonist nafadotride blocks the 
develqpment of behavioral sensitization to amphetamine (Richtand et al., 2000). The 
purpose of the present study, therefore, was to determine whether nafadotride 
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treatment would also block the development of behavioral sensitization to cocaine. 
Consequently, groups ofrats were treated daily with cocaine or saline combined with 
either saline or nafadotride, and tested for activity. Following the chronic treatment 
and a withdrawal interval, all rats were tested for activity after a challenge injection 
of cocaine. If the dopamine D3 receptors stimulation is crucial the development of 
behavioral sensitization.to cocaine, then concurrent nafadotride treatment should 





Thirty-one male Wistar albino rats (Harlan, Spraque Dawley, Indianapolis, 
IN) weighing between 250-300g at the beginning ofthe experiment, served as 
subjects. The rats were housed individually in standard wire-mesh cages in a colony 
room, which was temperature-controlled, and maintained on a 12-hour light dark 
cycle. All behavioral tests were conducted during the light cycle. Food and water 
were available continuously. 
Apparatus 
Behavioral activity was measured in four open field chambers (see Figure 1, 
' . 
Med Associates model OFA-163), and each chamber was located in an individual 
sound attenuated experimental cubicle. Each chamber was equipped with a 16 X 16 
array of photocell beams and detectors that were 2.5cm above the floor respectively. 
Another set of eight photocell beams and detectors were mounted 16 cm above the 
floor to measure rearing behavior. Signals from each individual photocell array were 
delivered to a Gateway-2000 computer with Med-Associate software placed in an 
adjacent room. Distance traveled ( cm), number ofrears, and stereotypic counts 
(small movements) were recorded at 10 min intervals. 
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Figure 1: Med-Associates locomotor activity testing chamber 
Drug 
Nafadotride was generously provided by Dr. Pierre Sokoloff (INSERM, Paris, 
France) and was dissolved in 0.9% saline. Nafadotride concentration was described 
as free base. Cocaine hydrochloride was also dissolved in 0.9% saline. Cocaine 
concentration was described as chlorinate salt. All injections were I. P. in a final 
volume of 1 ml/kg. 0.9% saline was used as vehicle injection. 
Design and Procedure 
This experiment was a 2 (cocaine dose: 0 or 15 mg/kg) X 2 (nafadotride dose: 
0 or 0.1 mg/kg) factorial design (see Table 1). 
Table 1 Experimental Design 
Cocaine (I. P.) 
Vehicle Nafadotride 
Nafadotride (I.Pl 
Vehicle N = 7 N=B 
Cocaine N=B N=B 
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The experiment was conducted in four phases: the habituation phase, the drug 
treatment phase, the conditioning test phase, and the cocaine challenge test. 
The habituation phase lasted two days. Each animal received a saline 
injection and 5 minutes later was placed in the activity chamber for 40 minutes. . . 
Animals were immediately returned to the home cages after the behavioral test. Based 
I 
on the distance traveled on day 2, the animals were assigned into the four drug I 
treatment groups: vehicle (saline), cocaine (15mg/kg), nafadotride (0.lmg/kg), and 
cocaine (15mg/kg) + nafadotride (0.lmg/kg). 
The drug treatment phase was conducted from Day 3 to Day 6. The procedure 
for this phase was the same as the habituation phase, except that the animals were 
injected with the assigned drugs 5 minutes prior to behavioral testing. 
The conditioning tests were conducted on the ?1h and sth day. The procedure 
was the same as the habituation phase in that all the animals were injected with saline 
before activity testing. 
The cocaine challenge test was conducted on Day 9. All subjects were 
injected with cocaine (15mg/kg). Five minutes after the injection, all the subjects 
were placed into the activity chambers. 
Data analysis 
Significant differences among the groups in mean distance traveled, the i 
i 
number of rears, and stereotypic counts during the habituation, drug treatment, i 
conditioning phase, and the cocaine challenge day were analyzed using 2 X 2 multi 
I 
I 
factorial analyses of variance (ANOVA). Drug treatment conditions were used as the 
11 
between factors; days and blocks of 10 min within each day were used as the within 
factors. Significant interactions were analyzed with additional ANOV As performed 
on individual session and/or block data, followed by Newman-Keuls tests. 
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Habituation Phase: Day 1 and 2 
Mean Distance Traveled 
Chapter3 
RESULT 
The mean distance traveled across blocks of ten minutes on the two 
habituation days for the four drug treatment groups is shown in Figure 2. A summary 
of the ANOVA performed on these data is displayed in Table 2 (Appendix A). As 
may be seen in Figure 2, the animals assigned to the four drug treatment conditions 
did not differ in distance traveled following the saline injection on Day 1 and 2. The 
ANO VA performed on these data revealed no significant drug effects (nafadotride 
effect: F < 1.00, and cocaine effect: F < 1.00; Nafadotride X Cocaine interaction 
effect: F < 1.00). In addition, all the subjects tended to show declines in distance 
traveled across days (day effect: F (1, 27) = 3.88, p = 0.06). As expected, there was a 
significant decrease in mean distance traveled across blocks and days on some blocks 
((block effect: F (3, 27) = 275.07, p < 0.001; Day X Block interaction effect: F (3, 27) 
= 4.06, p < 0.05). 
The mean number of rears for each of the four drug treatment groups across 
the four 10 min blocks of Day 1 and 2 is presented in Figure 3. A summary of the 
ANOVA performed on both days is presented in Table 3 (Appendix A). As may be 
























BLOCKS OF 10 MIN WITHIN EACH DAY 
Figure 2. Mean distance traveled (+ SEM) across blocks of 10 min on Day 1 
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BLOCKS OF 10 MIN WITHIN EACH DAY 
Figure 3. Mean number of rears (+ SEM) across blocks of 1 O min on Day 1 and 
2 for rats treated 5 min before each session with saline (VEH) injection. 
differ during these two sessions (nafadotride effect: F (1, 27) = 2.35, p > 0.05; 
cocaine effect: F < 1.00; Nafadotride X Cocaine interaction effect: F < 1.00). 
Overall, there was a significant decline in the mean number ofrears across blocks and 
days for some blocks (day effect: F (I, 27) = 21.22, p < 0.0001; block effect: F (3, 27) 
= 215.03, p < 0.0001; Day X Block interaction effect: F (3, 27) = 6.4, p < 0.01). 
Stereotypic Counts 
The mean stereotypic counts for each of the four drug treatment groups across 
the four 10 min blocks of Day 1 and 2 are presented in Figure 4. A summary of the 
ANOV A performed on these two days is presented in Table 4 (Appendix A). As may 
be seen in Figure 4, the four groups did not show significant difference in stereotypic 
counts (nafadotride effect: F < 1.00; cocaine effect: F < 1.00; Nafadotride X Cocaine 
interaction effect: F < 1.00). In addition, there were declines in stereotypic counts 
across days and blocks within each day (day effect: F (1, 27) = 9.90, p < 0.05; block 
effect F (3, 27) = 189.35, p < 0.0001). As expected, there was no significant 
difference in the stereotypic counts among these four groups before the drug 
treatment phase. 
Drug Treatment Phase: Day 3 to Day 6 
Mean Distance Traveled 
Figure 5 displays the mean distance traveled (in cm) for the four drug 
treatment groups on Day 3, 4, 5 and 6. A summary of the ANOVA performed on 
these four days is presented in Table 5 (Appendix A). As may be seen in Figure 5, 



























BLOCKS OF'10 MIN WITHIN EACH DAY 
Figure 4. Mean number of stereotypic counts ( + SEM) across blocks of 10 min on 
Day 1 and 2 for rats treated 5 min before each session with saline (VEH) injection. 
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BLOCKS OF 10 MIN WITHIN EACH DAY 
6 
Figure 5. Mean distance traveled (± SEM) across of 10 min on Day 3, 4, 5 and 6 for 
rats treated 5 min before test session with saline (VEH), 15 mg/kg cocaine (COC), 0.1 
mg/kg nafadotride (NAF) or 15 mg/kg COC + 0.1 mg/kg NAF injections. 
distance traveled (cocaine effect: F (1, 27) = 126.76, p < 0.0001). More important, 
the animals injected with cocaine tended to show increasing activities across days 
(Cocaine X Day interaction effect: F (3, 81) = 2.57, p = 0.06). Based on Newman-
Keuls"tests (p < 0.05), the subjects treated with cocaine produced a progressive 
increase in distance traveled (i.e., sensitization), while the vehicle groups maintained 
the same level of distance traveled. Although all drug treatments decreased distance 
traveled across blocks within each day, and this decrease was greater for the animals 
treated with cocaine (block effect: F (3, 27) = 201.91, p < 0.0001; Cocaine X Block 
interaction effect: F (3, 81) = 23.22, p < 0.0001). In contrast, repeated treatment with 
nafadotride did not significantly affect activity across either the days or blocks within 
each day (nafadotride effect: F < 1.00; Nafadotride X Day interaction effect: F < 
1.00; Nafadotride X Block interaction effect: F < 1.00). More important, nafadotride 
did not significantly affect cocaine-induced changes in distance traveled (Cocaine X 
Nafadotride interaction effect: F < 1.00). 
Rears 
Figure 6 shows the mean number ofrears for the four drug treatment groups 
on Day 3, 4, 5, and 6. A summary of the ANOVA performed on the four days is 
presented in Table 6 (Appendix A). As may be seen in Figure 6, there was an acute 
stimulation of the number of rears in the cocaine treatment groups, while injection 
with nafadotride did not significantly affect rearing behavior (cocaine effect: F (!, 27) 
= 19.13, p < 0.01; nafadotride effect: F < 1.00). Further, the stimulating effects of 
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Figure 6. Mean rears (± SEM) across of 10 min on Day 3, 4, 5 and 6 for rats treated 5 
min before test session with saline (VEH), 15 mg/kg cocaine (COC), 0.1 mg/kg 
nafadotride (NAF) or 15 mg/kg COC + 0.1 mg/kg NAF injections. 
F (3, 81) = 2.60, p < 0.06). Indeed, analysis of this interaction with Newman-Keuls 
tests (p<0.05) indicated that the cocaine treatment groups increased rearing from Day 
3 to Day 5. Repeated treatment with nafadotride did not significantly affect the 
number ofrears across either days or blocks within each day (Nafadotride X Day 
interaction effect: F (3, 81) = 1.21, p > 0.05; Nafadotride X Block interaction effect: F 
< 1.00). More important, nafadotride did not significantly affect cocaine-induced 
changes in the number ofrears (Cocaine X Nafadotride interaction effect: F < 1.00). 
Although the mean numbers ofrears overall did not significantly change across days, 
there was a decline in the number of rears across blocks within each day ( day effect: 
F (3, 81) = 1.83, p > 0.05; block effect: F (3, 81) = 66.69, p < 0.0001). 
Stereotypic counts 
Figure 7 presents the stereotypic counts for the four drug treatment groups 
from Day 3 to 6. A summary of the ANOVA performed on these four days is 
presented in Table 7 (Appendix A). As may be seen in Figure 7, the treatment with 
cocaine acutely stimulated stereotypic counts, while the injection with nafadotride did 
not display this effect (cocaine effect: F (1, 28) = 295.10, p < 0.0001; nafadotride 
effect: F< 1.00). Further, ANOV A analysis revealed a significant interaction effect 
between the cocaine and day (Cocaine X Day interaction effect: F (3, 81) = 2.88, p < 
0.05). This interaction, however, was due to the decline in stereotypes counts for the 
vehicle rats across days (Newman-Keuls, p < 0.05), rather than to an increase in 
stereotypic counts for the cocaine rats (Newman-Keuls, p > 0.05). In addition, there 
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6 
Figure 7. Mean stereotypic counts (± SEM) across blocks of 10 min on Day 3, 4, 5 and 
6 for rats treated 5 min before test session with saline (VEH), 15 mg/kg cocaine 
(COG), 0.1 mg/kg nafadotride (NAF) or 15 mg/kg COG + 0.1 mg/kg NAF injections. 
each day, and this decrease was smaller for rats treated with cocaine (block effect: F 
(3, 81}= 156.75, p < 0.0001; Cocaine X Block interaction effect: F (3, 81) = 22.93, P 
< 0.0001 ). In contrast, repeated treatment with nafadotride did not significantly affect 
stereotypic counts across either days or blocks within each day (Nafadotride X Day 
interaction effect: F < 1.00, Nafadotride X Block interaction effect: F < 1.00). More 
important, concurrent treatment of nafadotride and cocaine did not significantly affect 
the cocaine-induced stereotypic counts of the animals (Cocaine X Nafadotride 
interaction effect: F (1, 27) = 1.22, p > 0.05). 
Conditioning Test Phase: Day 7 and 8 
Mean Distance Traveled 
The mean distance traveled for each of the four drug treatment groups across 
the four 10 min blocks of Day 7 and 8 is presented in Figure 8. A summary of the 
ANOV A performed on both two days is presented in Table 8 (Appendix A). As may 
be seen in Figure 8, rats previously treated with cocaine were significantly more 
active after the saline injection, compared to rats not previously exposed to cocaine 
(cocaine effect: F (1, 27) = 33.15, p < 0.0001). As expected, this cocaine pre-
exposure effect was greatest during the first ten minutes of each session (Cocaine X 
Block effect: F (3, 81) = 10.23, p < 0.0001), and greater overall on the first session 
than on the second conditioning test session (Cocaine X Day interaction effect: F (1, 
27) = 36.35, p < 0.0001). Overall, nafadotride pretreatment did not significantly affect 
activity (nafadotride effect: F (1, 27) = 1.96, p > 0.05), but rats previously injected 
with nafadotride were more active than control rats on the first day (Nafadotride X 
23 
~ 
CONDITIONING TEST SESSIONS 
1500 
~ -D·VEH-VEH (.) -C 1250 ---vEH-COC 
w -O·NAF-VEH ...I w 
...... NAF-COC ! 1000 
I-
w 750 (.) 
~-
z 
l <( I- 500 ~ C ,, \ ' ,, 
\ ' \,\ z \ ' 
<( 250 \\~ \ w \ ,,,, :a 
:i!: 'b . , ----- ', ~-........ __ ',, 
0 ----- ---
7 8 
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Figure 8. Mean distance traveled (± SEM) across blocks of 1 O min on Day 7 and 8 for rats 
treated 5 min before each session with saline (VEH) injection. 
Day interaction effect: F (1, 27) = 5.45, p < 0.05). More important, concurrent 
pretreatment with nafadotride did not block the development of cocaine-induced 
conditioned hyperactivity (Cocaine X Nafadotride interaction effect: F (1, 27) = 1.12, 
p > 0.05). 
The number of rears for each of the four drug treatment groups across the four 
10 min blocks on Day 7 and 8 is presented in Figure 9. A summary of the ANOVA 
performed on these data is presented in Table 9 (Appendix A). As may be seen in 
Figure 9, the groups previously treated with cocaine displayed significantly higher 
number ofrears, suggesting a cocaine conditioning effect (cocaine effect: F (I, 27) = 
20.02, p < 0.001). In contrast, the groups with previous nafadotride treatment did not 
show significant change in the number ofrears (nafadotride effect: F (1, 27) = 1.43, p 
> 0.05). The animals tended to show declines in the number of rears across the four 
blocks within each day, and the animals previously treated with cocaine displayed a 
greater a decrease (block effect: F (3, 27) = 114.61, p < 0.0001; Cocaine X Block 
interaction effect: F (3, 81) = 6.39, p < 0.001). However, the subjects did not display 
significant changes in the number of rears across days ( day effect, F < 1.00). 
Furthermore, previous repeated treatment with nafadotride did not significantly affect 





















BLOCKS OF 10 MIN WITHIN EACH DAY 
Figure 9. Mean rears (± SEM) across blocks of 10 min on Day 7 and 8 for rats treated 5 
min before each session with saline (VEH) injection. 
Stereotypic Counts 
The mean stereotypic counts for each of the four drug treatment groups across 
these two days and four 10 min blocks within each day are presented in Figure 10. A 
summary of the ANOVA performed on both days is presented in Table 10 (Appendix 
A). As may be seen in Figure 10, rats previously treated with cocaine displayed 
significantly greater stereotypic counts across both conditioning test days ( cocaine 
effect: F (I, 27) = 55.42, p< 0.0001). As expected, this increased stereotypy decreased 
across both days and blocks within sessions (Cocaine X Day X Block interaction 
effect, F (3, 81) = 3.40, p < 0.05). Interestingly, nafadotride pretreatment also 
enhanced stereotypic counts (nafadotride effect: F (1, 27) = 3.98, p > 0.05), but only 
on the first test session (Nafadotride X Day interaction effect: F (1, 27) =4.54, p < 
0.05). Concurrent pretreatment with nafadotride and cocaine, however, did not affect 
the enhanced stereotypic response, compared to cocaine pretreatment alone 
(Nafadotride X Cocaine interaction effect: F < 1.00). 
Cocaine Challenge test: Day 9 
Mean Distance Traveled 
Figure 11 displays the mean distance traveled for the four pretreatment groups 
after the cocaine challenge injection. A summary of the ANOVA performed on this 
data is presented in Table 11 (Appendix A). Overall, as may be seen in the left panel, 
rats previously treated with cocaine were significantly more active following the 

























BLOCKS OF 10 MIN WITHIN EACH DAY 
Figure 10. Mean stereotypic counts (± SEM) across blocks of 10 min on Day 7 and 8 for 
rats treated 5 min before each session with saline (VEH) injection. 
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Figure 11. Mean distance traveled (+ SEM) after a cocaine challenge injection (day 9) for the animals 
previously treated either saline (VEH) or 15mg/kg Cocaine (COG) in combination with either saline (VEH) 
or 0.1 mg/kg Nafadotride (NAF). The left panel represents the total day activity and the right panel presents 
the same data as a function of four 1 O min blocks within the day. 
indicating the development of behavioral sensitization to cocaine ( cocaine effect: F 
(1, 27) = 15.30, p < 0.00 I). Overall, nafadotride pretreatment did not significantly 
affect responsiveness to the cocaine challenge injection (nafadotride effect: F (1, 27) 
= 2.94, P > 0.05). However, as may be seen in the right panel of Figure 11, 
nafadotride pretreated rats were more active than vehicle pretreated rats on the early 
blocks of the test session (Nafadotride X Block interaction effect: F (3, 81) = 2.97, p 
< 0.05). Indeed, Newman-Keuls analysis of this interaction indicated that nafadotride 
pretreated rats were significantly more active than vehicle rats on the first three 
blocks of this session (P < 0.05 in each case). Similarly, the effect of cocaine 
pretreatment declined across blocks (Cocaine X Block interaction effect: F (3, 81) = 
5.53, p < 0.01). Although rats pretreated with both cocaine and nafadotride displayed 
the greatest responsiveness to the cocaine challenge injection, nafadotride did not 
significantly enhance cocaine-induced sensitization (Nafadotride X Cocaine 
interaction effect: F < 1.00; Nafadotride X Cocaine X Block interaction effect, F (3, 
81) = 1.36, p > 0.05). It is clear from these results that concurrent pretreatment with 
nafadotride did not block the development of behavioral sensitization to cocaine as 
measured by horizontal locomotor activity. 
Rears 
Figure 12 displays the mean numbers ofrears for the four pretreatment groups 
after the cocaine challenge injection. A summary of the ANOVA performed on this 
data is presented in Table 12 (Appendix A). Overall, the animals treated previously 
with cocaine displayed an increase in subsequent behavioral sensitivity to cocaine on 
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Figure 12. Mean rears(+ SEM) after a cocaine challenge injection (day 9) for the animals previously treated 
either saline (VEH) or 15mg/kg Cocaine (C0C) in combination with either saline (VEH) or 0.1 mg/kg Nafadotride 
(NAF). The left panel represents the total day activity and the right panel presents the same data as a function of 
four 1 O min blocks within the day. 
the challenge day, while prior treatment with nafadotride did not significantly affect 
rearing behavior (cocaine effect: F (1, 27) = 4.16, p < 0.06; nafadotride effect: F < 
1.00) .. As shown on the right panel, there tended to be declines in the number of rears 
among all the subjects across blocks (block effect, F (3, 27) = 27.47, p < 0.0001). 
More important, the concurrent treatments of nafadotride and cocaine did not block 
the development of sensitization to cocaine (Nafadotride X Cocaine interaction effect: 
F< 1.00). 
Stereotypic Counts 
Figure 13 displays the mean stereotypic for the four pretreatment groups after 
the cocaine challenge injection. A summary of the ANOVA performed on this data is 
presented in Table 13 (Appendix A). Overall, as may be seen in the left panel, prior 
treatment with cocaine also produced a significant increase in subsequent stereotypic 
counts, which was the proof of the behavioral sensitization to cocaine ( cocaine effect: 
F (1, 27) = 4.31, p < 0.05). In addition, prior treatment with nafadotride also tended 
to increase cocaine-induced stereotypy (nafadotride effect: F (1, 27) = 4.13, P < 
0.06). As shown on the right panel, each group tended to show a decrease in the 
stereotypic counts across blocks (block effect, F (3, 27) = 41.65, p < 0.0001 ). More 
important, concurrent treatments ofnafadotride and cocaine did not significantly 
block cocaine-induced sensitization of stereotypy (Nafadotride X Cocaine interaction 
effect: F < 1.00). 
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Figure 13. Mean stereotypic counts ( + SEM) after a cocaine challenge injection (day 9) for the animals 
previously treated either saline (VEH) or 15mg/kg Cocaine (COC) in combination with either saline (VEH) or 
0.1 mg/kg Nafadotride (NAF). The left panel represents the total day activity and the right panel presents the 
same data as a function of four 1 O min blocks within the day. 
Chapter4 
Discussion 
The current results clearly indicate that repeated exposure to cocaine results in 
the development of behavioral sensitization. During the pretreatment sessions, 
cocaine produced a progressive increase in distanced traveled and rearing, but not 
stereotypic movements, compared to a steady decline in locomotor behaviors across 
days for rats treated with only saline. Similarly, the subsequent challenge injection of 
cocaine, after a two-day withdrawal interval, produced a significantly greater increase 
in horizontal locomotor activity and rearing in rats previously treated with cocaine 
compared to rats receiving cocaine for the first time. These results are consistent with 
previous studies conducted in our laboratory (Mattingly et al., 1994; 1996) and others 
(e.g., Kalivas, Duffy, DuMars & Skinner, 1988), suggesting that the development of 
behavioral sensitization is a reliable and robust phenomenon. 
In contrast to cocaine, the acute administration of the putative selective 
dopamine D3 receptor antagonist, nafadotride, did not significantly affect any of the 
three measures of activity during the four pretreatment sessions. As noted previously, 
a great deal of evidence suggests that dopamine D3 receptors are inhibitory with 
respect to the generation oflocomotor behavior (Richtand, et al., 200 l ). Consistent 
with this view, a number of studies have reported that stimulation of dopamine D3 
receptors with selective agonists such as 7-OH-DPAT (Mattingly et al., 1996) or PD 
128, 907 (Prinssen et al., 1998), produced a significant suppression oflocomotor 
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activity. Based on these data, it would be predicted that selective antagonism of 
inhibitory dopamine D3 receptors with nafadotride should result in a significant 
increase in activity. However, this was not the case in the current experiment. In 
contrast to the lack oflocomotor effects with nafadotride, it has been reported that the 
putative selective dopamine D3 receptor antagonist U99194A does acutely increase 
locomotor activity (Kling-Petersen, Ljung & Svensson, 1995; Waters, Svensson, 
Haadsma-Svensson, Smith & Carlsson, 1993; Mattingly et al., 2000). At present, the 
nature of this discrepancy is unclear. Although this conflict could be due to the 
different selective antagonists (i.e., nafadotride vs U99194A) used, it also could be 
due to the number of methodological differences among the studies reporting 
conflicting results. The current study used a dose of nafadotride slightly above that 
reported to block the development of behavioral sensitization to amphetamine 
(Richtand et al., 2000). Unfortunately, in that study the effect of nafadotride alone on 
locomotor activity was not determined. It should be noted however, that although 
nafadotride did not enhance activity in the current study, unlike dopamine D2 
receptor antagonist such as haloperidol and eticlopride (Mattingly, Rowlett, Ellison & 
Rase, 1996; White et al., 1998), nafadotride did not decrease activity, either. The lack 
of a nafadotride-induced decrease in activity is consistent with the view that the 
functional properties of dopamine D3 receptors differ significantly from dopamine 
D2 receptors (See Ekman et al., 1998; Sautel et al., 1995 for review). 
Consistent with the lack of effect of nafadotride alone, the concurrent 
treatment of nafadotride with cocaine during the pretreatment sessions did not 
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significantly affect the level of cocaine-induced activity either acutely or across 
sessions. Again, based upon the hypothesis that dopamine D3 receptors are inhibitory 
with respect to locomotor behavior, it was expected that nafadotride administered 
with cocaine should have increased the stimulating effects of cocaine. However, this 
was not the case. Further, this finding is inconsistent with the previous finding in this 
lab that the selective dopamine D3 agonist, 7-OH-DPAT, attenuates the acute effects 
of cocaine (Mattingly et al., 1996). Likewise, it has been reported that co-
administration of the dopamine D3 antagonist U99194A with amphetamine enhances 
the locomotor-stimulating effects of amphetamine (Kling-Petersen et al. , 1995). It 
is, of course, possible that the dose of nafadotride used in the current study was too 
low to significantly affect activity alone or to affect cocaine-induced activity. 
However, a lower dose than used in the present study was reported to block the 
development of sensitization to amphetamine (Richland et al., 200 t ), and the dose 
used in the current study was the highest possible to maintain selectivity for D3 
receptors (Levant & Vansell, 1997). Doses greater that 0.10 mg/kg have been 
reported to have significant effects on dopamine D2-type receptors (Levant & 
Vansell, 1997). 
During the two drug withdrawal days, rats previously treated with cocaine 
were hyperactive, compared to saline control rats, when placed into the activity test 
chambers without cocaine. Indeed, cocaine pretreated rats displayed significantly 
greater levels of all three measures of locomotor behavior ( distanced traveled, 
rearing, and stereotypy) after the saline injections compared to control rats. This 
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finding is consistent with previous research with cocaine and other psychostimulants 
(e.g., Carey, Damianopoulos & DePalma, 1999), and has usµally been interpreted 
within the context of classical conditioning (Le Foll, Frances, Diaz & Schwartz, 
2002). In this model, it is assumed that_ cocaine serves as an unconditioned stimulus 
(UCS) that elicits an unconditioned response (UCR) of hyperactivity. With repeated 
cocaine treatments, the activity test environment becomes a conditioned stimulus 
(CS), which can then elicit a conditioned response (CR) of hyperactivity in the 
absence of cocaine. Although the current results are consistent with this 
interpretation, alternative explanations cannot be eliminated with the current design 
(see, Carey et al., 1999, for review). For example, in the current study, rats previously 
treated with nafadotride displayed a significant increase in distanced traveled and 
stereotypy counts, after the saline injections during the conditioning test. It is hard to 
argue that this nafadotride-induced increased activity response is due to classical 
conditioning since nafadotride did not affect activity during the pretreatment sessions. 
As discussed previously, rats previously treated with cocaine displayed 
significantly greater horizontal activity (distance traveled), vertical activity (rears), 
and stereotypic small movements after the cocaine challenge injection than rats 
receiving cocaine for the first time. In contrast, prior treatments with nafadotride 
alone did not significantly affect subsequent sensitivity to cocaine as measured by 
either distance traveled or rearing. Nafadotride pretreatments did, however, result in a 
slightly enhanced increase in cocaine-induced stereotypy counts during the cocaine 
challenge test. As previously mentioned, rats previously treated with nafadotride 
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alone also displayed an increase in stereotypy counts after saline injections during the 
withdrawal interval. Neither of these effects was expected, and at present, the 
mechanism responsible for these effects is not clear. 
During the pretreatment sessions, concurrent treatments with nafadotride and 
cocaine did not attenuate or block the progressive increases observed in cocaine-
induced locomotor activity over the four pretreatment days. This finding suggests that 
nafadotride did not block the development of behavioral sensitization to cocaine. The 
results of the cocaine challenge test confirm this interpretation. That is, rats treated 
with nafadotride and cocaine during the pretreatment sessions did not significantly 
differ from rats previously treated with only cocaine on any measure oflocomotor 
behavior during the cocaine challenge test. In fact, rats pretreated with both 
nafadotride and cocaine displayed greater (but not significantly) distance traveled 
after the cocaine challenge injection than rats previously treated with cocaine alone. 
These findings clearly indicate that nafadotride did not block the development of 
behavioral sensitization to cocaine. 
The present study was designed to test the hypothesis that repeated dopamine 
D3 receptor stimulation is a critical factor mediating the development of behavioral 
sensitization to psychostimulant drugs (Richtand et al., 2001 ). Assuming that 
nafadotride effectively blocked dopamine D3 receptors in the current study, the 
present results are clearly inconsistent with this hypothesis. These results contrast 
with a recent study that reported that the co-administration of nafadotride with 
amphetamine blocked the development of behavioral sensitization to amphetamine 
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(Richtand et al., 2001 ). Although the discrepant findings between the current 
experiment using cocaine compared to those of the previous study using 
amphetamine may be related to methodological factors, the design of the present 
study was modeled after the amphetamine experiment (Richland ~t al., 2000). Indeed, 
the number and duration of the habituation, pretreatment, withdrawal, and challenge 
sessions was the same as in the previous study. Similarly, it is possible that 
nafadotride did not sufficiently block dopamine D3 receptors in the current study to 
prevent sensitization to cocaine. But as noted 'previously, we used the highest dose 
reported to be selective for dopamini;; D3 receptors (Sautel, et al., 1995). Moreover, in 
a previous study, we found nearly identical results using the preferential dopamine 
D3 receptor antagonist U99 l 94A (Mattingly et al., 2000). Thus, it seems likely that 
the differential effectiveness ofnafadotride in blocking the development of behavioral 
sensitization to amphetamine and cocaine may be more related to differences in the 
mechanism of action of the psychostimulants than to methodological or other factors. 
Assuming that nafadotride in the current study and U99 l 94A in our previous study 
(Mattingly et al., 2000), effectively blocked dopamine D3 receptors, the results of 
these two studies suggest that a differential down-regulation of dopamine D3 vs D2 
receptors is not responsible for the development of behavioral sensitization to 
cocame. 
The differential effects of the preferential dopamine D3 receptor antagonist, 
nafadotride, on amphetamine- and cocaine-induced behavioral sensitization is not the 
only reported differences in dopamine receptor involvement in the induction of 
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behavioral sensitization to these two drugs and other dopamine agonists. For 
example, the dopamine DI receptor antagonist SCH 23390 has been reported to block 
the development of behavioral sensitization to the indirect agonist amphetamine 
(Stewart & Vezina, 1989; Drew & Glick, 1990), as well as to the direct nonselective 
dopamine agonist apomorphine (Mattingly et al., 199 I). In contrast, several studies 
have demonstrated that although SCH 23390 blocks the acute effects of cocaine, 
concurrent treatments with SCH 23390 and cocaine does not prevent the development 
of behavioral sensitization to cocaine (Mattingly et al., 1994; 1996; White et al., 
1998). Thus, at present, both selective DI and D3, but not D2, dopamine receptor 
antagonists have been found to block the development of amphetamine-induced 
behavioral sensitization (Drew & Glick, 1990; Richland et al., 2000). In contrast, 
selective D 1, D2, and D3 dopamine antagonists are not effective in attenuating or 
blocking the development of behavioral sensitization to cocaine (Mattingly et al., 
I 994; 1996; 2000). Taken together, these findings suggest that the stimulation of 
dopamine receptors may not be necessary for the development of behavioral 
sensitization to cocaine. Since cocaine blocks the reuptake of other monoamines (e.g., 
serotonin, norepinephrine) besides dopamine, it is possible that these other 
neurotransmitters play a more important role in the development of behavioral 
sensitization to cocaine. Currently, several laboratories are evaluating this possibility 
(e.g., Muller, Carey, De Souza Silva, Jocham, & Huston, 2002). 
In conclusion, the current findings clearly indicate that concurrent nafadotride 
treatment does not block the development of behavioral sensitization to cocaine. This 
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finding is inconsistent with the hypothesis that the development of behavioral 
sensitization to cocaine is mediated by dopamine D3 receptor stimulation. Assuming 
that dopamine D3 receptor stimulation is critical to the development of behavioral 
sensitization to amphetamine and other psychostimulant drugs, the current results 
suggest that the development of behavioral sensitization to different psychostimulant 
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Summary of Analysis of Variance Performed on Mean Distance Traveled during the 
Habituation Phase (Day 1 and 2) 
Source DF Mean Square FValue Pr>F 
Between Groups 
Nafadotride (N) 1 55743 0.33 0.5710 
Cocaine (C) 1 89156 0.53 0.4744 
NXC 1 30042 0.18 0.6770 
Error 27 169430 
Within Groups 
Day(D) 1 160766 3.88 0.0593* 
NXD 1 2934 0.07 0.7923 
CXD 1 440 0.01 0.9179 
NXCXD 1 16742 0.40 0.5306 
Error 27 41486 
Block (B) 3 7771773 275.07 <.0001 * 
NXB 3 10336 0.37 0.7779 
CXB 3 24757 0.88 0.4570 
NXCXB 3 12957 0.46 0.7120 
Error 81 28254 
BXD 3 95905 4.06 0.0096* 
NXBXD 3 17798 0.75 0.5230 
CXBXD 3 8586 0.36 0.7792 
NXCXBXD 3 27141 1.15 0.3339 
Error 81 23594 
* Significant effect 
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Table 3 
Summary of Analysis of Variance Performed on Mean Number of Rears during the 
Habituation Phase (Day 1 and 2) 
Source DF Mean Square FValue Pr>F 
Between Groups 
Nafadotride (N) 1 1662 2.35 0.1368 
Cocaine (C) 1 5 0.01 0.9348 
NXC 1 112 0.16 0.6935 
Error 27 707 
Within Groups 
Day(D) 1 4722 21.22 <.0001 * 
NXD 1 2 0.01 0.9309 
CXD 1 0 0.00 0.9699 
NXCXD 1 15 0.07 0.7973 
Error 27 223 
Block (B) 3 48573 215.03 <.0001 * 
NXB 3 80 0.35 0.7874 
CXB 3 165 0.73 0.5361 
NXCXB 3 91 0.40 0.7520 
Error 81 226 
BXD 3 752 6.40 0.0006* 
NXBXD 3 204 1.74 0.1658 
CXBXD 3 1 0.01 0.9982 
NXCXBXD 3 275 2.34 0.0793 
Error 81 118 
* Significant effect 
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Table4 
Summary of Analysis of Variance Performed on Mean Number of Stereotypic Counts 
during the Habituation Phase (Day 1 and 2) 
Source DF Mean Square FValue Pr<F 
Between Groups 
Nafadotride (N) I 332047 0.64 0.4301 
Cocaine (C) 1 195880 0.38 0.5435 
NXC 1 312165 0.60 0.4441 
Error 27 517399 
Within Groups 
Day(D) 1 1574921 9.90 0.0040* 
NXD 1 37152 0.23 0.6328 
CXD I 23168 0.15 0.7057 
NXCXD 1 2162 0.01 0.9080 
Error 27 159050 
Block (B) 3 22541156 189.35 <.0001 * 
NXB 3 34663 0.29 0.8316 
CXB 3 15487 0.13 0.9419 
NXCXB 3 33215 0.28 0.8404 
Error 81 119043 
BXD 3 133016 1.49 0.2223 
NXBXD 3 20001 0.22 0.8790 
CXBXD 3 31269 0.35 0.7883 
NXCXBXD 3 74782 0.84 0.4758 
Error 81 89021 
* Significant effect 
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Table 5 
Summary of Analysis of Variance Performed on Mean Distance Traveled during the 
Drug Treatment Phase (Day 3 to 6) 
Source DF Mean Square FValue Pr>F 
Between Groups 
Nafadotride (N) I 91317 0.04 0.8406 
Cocaine (C) I 280658911 126.76 <.0001 * 
NXC I 234854 0.11 0.7472 
Error 27 2214097 
Within Groups 
Day(D) 3 1014258 1.40 0.2478 
NXD 3 512893 0.71 0.5490 
CXD 3 1857080 2.57 0.0600* 
NXCXD 3 485236 0.67 0.5720 
Error 81 722729 
Block(B) 3 16377402 201.91 <.0001* 
NXB 3 37106 0.46 0.7128 
CXB 3 1883520 23.22 <. 0001 * 
NXCXB 3 84108 1.04 0.3808 
Error 81 81112 
BXD 3 42882 1.02 0.4218 
NXBXD 3 13244 0.32 0.9693 
CXBXD 3 36752 0.88 0.5463 
NXCXBXD 3 43076 1.03 0.4181 
Error 81 41902 
* Significant effect 
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Table 6 
Summary of Analysis of Variance Performed on Mean Number of Rears during the 
Drug Treatment Phase (Day 3 to 6) 
Source DF Mean Square FValue Pr>F 
. Between Groups 
Nafadotride (N) 1 2 0.00 0.9887 
Cocaine (C) 1 184291 19.13 0.0002* 
NXC 1 · 799 0.08 0.7756 
Error 27 9636 
Within Groups 
Day(D) 3 2224 1.83 0.1481 
NXD 3 1472 1.21 0.3108 
CXD 3 3160 2.60 0.0577* 
NXCXD 3 1423 1.17 0.3258 
Error 81 1215 
Block (B) 3 35172 66.69 <.0001 * 
NXB 3 83 0.16 0.9248 
CXB 3 1251 2.37 0.0764 
NXCXB 3 1285 2.44 0.0706 
Error 81 527 
BXD 3 535 2.83 0.0035* 
NXBXD 3 161 0.85 0.5898 
CXBXD 3 49 0.26 0.9842 
NXCXBXD 3 325 1.72 0.0853 
Error· 81 189 
* Significant effect 
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Table 7 
Summary of Analysis of Variance Performed on Mean Number of Stereotypic Counts 
during the Drug Treatment Phase (Day 3 to 6) 
Source DF Mean Square FValue Pr>F 
Between Groups 
N afadotride (N) 1 34838 0.38 0,5415 
Cocaine (C) I 268891784 295.10 <.0001 * 
NXC I 1109646 1.22 0.2795 
Error 27 · 911189 
Within Groups 
Day (D) 3 9181 0.02 0.9958 
NXD 3 265896 0.61 0.6113 
CXD 3 1259184 2.88 0.0408* 
NXCXD 3 537932 1.23 0.3037 
Error 81 436841 
Block (B) 3 18697052 156.75 <.0001 * 
NXB 3 87758 0.74 0.5337 
CXB 3 2735617 22.93 <.0001 * 
NXCXB 3 307444 2.58 0.0594 
Error 81 119281 
BXD 3 79839 1.61 0.1138 
NXBXD 3 52489 1.06 0.3960 
CXBXD 3 16134 0.32 0.9664 
NXCXBXD 3 106751 2.15 0.0263* 
Error 81 49687 
* Significant effect 
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Table 8 
Summary of Analysis of Variance Performed on Mean Distance Traveled during the 
Drug Conditioning Test Phase (Day 7 and 8) 
Source DF Mean Square FValue Pr>F 
Between Groups 
Nafadotride (N) 1 393209 1.96 0.1724 
Cocaine (C) 1 6633233 33.15 <.0001 * 
NXC I 224251 1.12 0.2992 
Error 27 200120 
Within Groups 
Day (D) 1 87713 2.71 0.1110 
NXD 1 176235 5.45 0.0272* 
CXD 1 20508 36.35 0.0180* 
NXCXD 1 26821 0.83 0.3703 
Error 27 32315 
Block (B) 3 5681737 149.91 <.0001 * 
NXB 3 12002 0.32 0.8133 
CXB 3 387584 10.23 <.0001 * 
NXCXB 3 5060 0.13 0.9398 
Error 81 37901 
BXD 3 15286 0.93 0.4287 
NXBXD 3 13715 0.84 0.4774 
CXBXD 3 59258 3.62 0.0166* 
NXCXBXD 3 12608 0.77 0.5144 
Error 81 16384 
* Significant effect 
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Table 9 
Summary of Analysis of Variance Performed on Mean Number of Rears during the 
Conditioning Test Phase (Day 7 and 8) 
Source DF Mean Square F Value Pr>F 
Between Groups 
Nafadotride (N) 1 1240 1.43 0.2422 
Cocaine (C) 1 17363 20.02 0.0001 * 
NXC I 330 0.38 0.5425 
Error 27 867 
Within Groups 
Day(D) 1 6 0.03 0.8550 
NXD 1 317 1.92 0.1777 
CXD 1 49 0.30 0.5910 
NXCXD 1 1 0.01 0.9316 
Error 27 166 
Block(B) 3 20739 114.61 <.0001* 
NXB 3 72 0.40 0.7541 
CXB 3 1133 6.26 0.0007* 
NXCXB 3 48 0.27 0.8484 
Error 81 181 
BXD 3 11 0.12 0.9458 
NXBXD 3 44 0.50 0.6809 
CXBXD 3 102 1.15 0.3326 
NXCXBXD 3 ·176 2.00 0.1202 
Error 81 '88 
* Significant effect 
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Table 10 
Summary of Analysis of Variance Performed on Mean Number of Stereotypic Counts 
during the Conditioning Test Phase (Day 7 and 8) 
Source DF Mean Square FValue Pr>F 
Between Groups 
Nafadotride (N) I 1456187 3.98 0.0562* 
Cocaine (C) 1 20277548 55.42 <.0001 * 
NXC 1 242518 0.66 0.4227 
Error 27 365857 
Within Groups 
Day(D) 1 387366 3.90 0.0586* 
NXD 1 450729 4.54 0.0424* 
CXD 1 328433 3.31 0.0802 
NXCXD 1 247486 2.49 0.1262 
Error 27 99362 
Block (B) 3 14032552 133.05 <.0001 * 
NXB 3 79067 0'.75 0.5257 
CXB 3 121746 1.15 0.3324 
NXCXB 3 50372 0.48 0.6987 
Error 81 105468 
BXD 3 5596 0.09 0.9664 
NXBXD 3 47310 0.74 0.5288 
CXBXD 3 215895 3.40 0.0217* 
NXCXBXD 3 38813 0.61 0.6101 
Error 81 63574 
* Significant effect 
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Table 11 
Summary of Analysis of Variance Performed on Mean Distance Traveled during the 
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Squad# Subject# Drug Treatment Group Chamber 
I I vehicle-vehicle 1 
1 4 vehicle-cocaine 2 
I 3 nafadotride-vehicle 3 
1 2 nafadotride-cocaine 4 
2 7 nafadotride-vehicle I 
2 8 nafadotride-cocaine 2 
2 6 vehicle-vehicle 3 
2 5 vehicle-cocaine 4 
3 11 vehicle-cocaine I 
3 12 vehicle-vehicle 2 
3 9· nafadotride-cocaine 3 
3 10 nafadotride-vehicle 4 
4 16 nafadotride-cocaine 1 
4 15 nafadotride-vehicle 2 
4 14 vehicle-cocaine 3 
4 13 vehicle-vehicle 4 
5 17 vehicle-cocaine 1 
5 20 vehicle-vehicle 2 
5 18 nafadotride-cocaine 3 
5 19 nafadotride-vehicle 4 
6 23 nafadotride-cocaine 1 
6 21 nafadotride-vehicle 2 
6 24 vehicle-cocaine 3 
6 .22 vehicle-vehicle 4 
7 26 vehicle-vehicle I 
7· 27 vehicle-cocaine 2 
7 28 nafadotride-vehicle 3 
7 25 nafadotride-cocaine 4 
8 29 nafadotride-vehicle 1 
8 30 nafadotride-cocaine 2 
8 31 vehicle-cocaine 4 
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